Stay updated with breaking news from Johnn Allan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
John N. Allan, MD, discusses the importance of understanding fixed-duration treatment approaches with BTK inhibitors and BCL2 inhibitors in patients with chronic lymphocytic leukemia, highlighting data within this treatment armamentarium.
John N. Allan, MD, discusses current data detailing the activity of venetoclax-based, fixed-duration regimens in the frontline setting for patients with chronic lymphocytic leukemia; the synergy and promising efficacy signals seen with BCL-2 and BTK inhibitor combinations; and ongoing research efforts exploring triplet regimens vs other continuous approaches in this space.
John N. Allan, MD, discusses a planned evaluation of obinutuzumab triplet consolidation therapy for patients with chronic lymphocytic leukemia /small lymphocytic lymphoma who remain minimal residual disease–positive after initial treatment with zanubrutinib and venetoclax .
Treatment with fixed-duration ibrutinib plus venetoclax for patients with chronic lymphocytic leukemia in the first-line setting elicited durable responses and sustained progression-free survival outcomes regardless of high-risk genomic features.
TUESDAY, June 13, 2023 (HealthDay News) -- Fixed-duration ibrutinib plus venetoclax is beneficial for patients with chronic lymphocytic leukemia, including those with high risk features, according to a study published